Evidence map›Paper›PMID 40650732›Full record

ArticleMolecular diversity2026

Structure-based cheminformatics and molecular dynamics profiling of potential SIRT6 inhibitors.

Ali Al-Samydai, Farah Al-Mamoori, Amal Mayyas, Amjad Ibrahim Oraibi, Hany Akeel Al-Hussaniy, Ali Almukram, Faiyaz Shakeel

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ali Al-SamydaiPharmacological and Diagnostic Research Centre, Faculty of Pharmacy, Al-Ahliyya Amman University, Amman, Jordan.
Farah Al-MamooriDepartment of Pharmaceutical Sciences, Faculty of Pharmacy, Zarqa University, Zarqa, Jordan.
Amal MayyasDepartment of Pharmacy, Faculty of Health Sciences, American University of Madaba, Madaba, Jordan.
Amjad Ibrahim OraibiDepartment of Pharmacy, Al-Manara College for Medical Sciences, Maysan, Iraq. amjadibrahim@uomanara.edu.iq.
Hany Akeel Al-HussaniyDepartment of Pharmacology, Collage of Pharmacy, Al-Nisour University College, Baghdad, Iraq.
Ali AlmukramUniversity of Maryland, Baltimore, USA.
Faiyaz ShakeelDepartment of Pharmaceutics, College of Pharmacy, King Saud University, 11451, Riyadh, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sirtuin-6 (SIRT6) is a NAD+-dependent deacetylase that maintains genome stability, metabolic regulation, and cellular stress responses, making it an attractive target for therapeutic intervention in metabolic and age-related diseases. Despite its biological importance, the identification of potent SIRT6 modulators remains limited. In this study, we applied an integrative computational approach combining cheminformatics, network pharmacology, molecular docking, and molecular dynamics simulations to explore new inhibitory candidates targeting SIRT6. A curated dataset of 78 CHEMBL compounds was used to develop robust multi-fingerprint QSAR models using Random Forest algorithms, validated through Y-randomization, external testing, and applicability domain analysis. Network pharmacology analysis revealed functional associations between SIRT6 and key regulatory proteins such as NAMPT, CD38, and HIF1A, highlighting its involvement in NAD⁺ biosynthesis and cellular stress pathways. Molecular docking identified CHEMBL50 (Quercetin) and CHEMBL4217987 as top candidates with favorable interactions at the SIRT6 catalytic site. These complexes were further evaluated through 200 ns MD simulations. Binding stability was confirmed using MM-GBSA free energy calculations, dynamic cross-correlation matrix (DCCM), and principal component analysis (PCA), demonstrating energetically favorable and stable protein-ligand interactions. Overall, this study offers a predictive and mechanistic framework for SIRT6 inhibitor discovery and provides lead scaffolds for further optimization and experimental validation.

Indexed as

CheminformaticsMolecular Dynamics SimulationSirtuinsHumansMolecular Docking SimulationQuantitative Structure-Activity RelationshipSIRT6 protein, humanSirtuinsMM-GBSA binding energyMolecular dockingMolecular dynamics simulationNetwork pharmacologyQSAR modelingSirtuin-6 (SIRT6)

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.